Top 25 orphan drugs, by 2015 global sales
Roche’s Rituxan generated $7.3 billion in sales in 2015, making it the top-selling orphan drug.
Orphan Drug
Orphan drug sales expected to grow 12% by 2020
Click for an infographic to learn more about orphan drugs, rare diseases and the top-selling drugs in the category.
Five things for pharma marketers to know: Wednesday, July 8
CDC report finds prescription painkiller abuse contributed to an increase in heroin use; Novartis heart-failure drug gets FDA approval; Isis Pharmaceuticals obtains orphan-drug designation for volanesorsen
Five things for pharma marketers to know: Thursday, July 2
Biogen pursues orphan eye-disease treatments; Novo Nordisk will stop selling Tresiba in Germany over price controversy; the switch to Prevnar 13 is expected to lower costs
Everyday Health looks to compete for pharma TV budgets
The digital health firm is expanding services to pharma customers, offering to help drugmakers maximize spending on TV and video.
Five things for pharma marketers to know: Monday, April 6
Pfizer exec said biosimilar interchangeability definition not happening anytime soon; AARP launches digital health tech studies with Pfizer and UnitedHealthcare; BMS inks gene therapy collaboration deal
Horizon makes $1.1-billion rare-disease push
Horizon Pharma’s purchase of Hyperion Therapeutics will add two rare-disease drugs to its portfolio.
Shire and Cincinnati Children’s Hospital team up in rare diseases
The duo hope to begin testing a new treatment within three years.
Everyday Health buys rare-disease agency Cambridge BioMarketing
The $38-million deal expands the reach of rare-disease campaigns.
Five things for pharma marketers to know: Monday, March 23
Eleven new drugs with blockbuster potential are expected to launch this year; a bill would require FDA to quickly review drugs approved in the EU; Biogen reinforces its focus on hard-to-treat diseases
